ERK expression and its correlation with STAT1 in esophageal squamous cell carcinoma

Hu Wang1,*, Ying Zhang2,*, Hailong Yun2, Shubiao Chen1, Yelong Chen1 and Zhaoyong Liu1

1Department of Orthopaedics, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
2Department of Pathology, Shantou University Medical College, Shantou, Guangdong Province, China
*These authors contributed equally to this work

Correspondence to: Zhaoyong Liu, email: langtian07@hotmail.com

Keywords: ESCC, ERK, p-ERK STAT1, immunohistochemistry

ABSTRACT

Background: Esophageal squamous cell carcinoma is one of leading causes of cancer-related deaths in Chaoshan region a high-risk region for esophageal cancer. Extracellular regulated protein kinases (ERK) usually play an important role in cell proliferation and differentiation. However, accumulating evidence has shown that the ERK was aberrantly expressed in cancers and correlated with STAT1 depression.

Results: The activated ERK downregulates STAT1 expression in ESCC cell lines and U0126 increases expression of STAT1. Our immunohistochemistry result also confirms that the expression of ERK inversely correlated with that of STAT1 in ESCC tumors. In addition, a significantly higher expression of ERK/p-ERK was found in ESCC tissues in comparison with case-matched normal esophageal tissues (p < 0.05). Moreover, the immunohistochemical analysis demonstrated that ERK expression was paralleled with the differentiation and clinical stage. In 74 patients with follow-up data, those with ERKlow tumors survived significantly longer than those with ERKhigh tumors (p = 0.04); patients with ERKlow/STAT1high tumors had the longest survival (p = 0.001).

Materials and Methods: To investigate whether ERK can mediated STAT1 expression in ESCC, we used the MEK plasmid and U0126, a MEK inhibitor, to treat the cell. To further confirm our in-vitro study, we detected the ERK, p-ERK and STAT1 expression in 131 ESCC cases and 22 case-matched normal esophageal tissues adjacent to the tumors specimens.

Conclusions: These findings provide pathological evidence that ERK/p-ERK is negatively correlated with STAT1 in ESCC. Our data suggests that inhibition of ERK and/or restoration of STAT1 expression maybe useful therapeutic strategies for ESCC.

INTRODUCTION

The mitogen-activated protein kinase (MAPK)-extracellular regulated protein kinases (ERK) signaling pathway is a major regulator in a wide range of cellular processes such as cell proliferation, differentiation, survival and motility [1]. ERK activation has been implicated in the pathogenesis and progression of various cancer types, such as cancers of prostate, kidney and colon [2]. ERK represents an attractive anti-cancer therapeutic target for the development of anticancer drugs. However, studies related to the ERK signaling pathway in ESCC are limited.

Signal transducers and activators of transcription (STATs) are critical mediators of cytokine signaling. Upon cytokine stimulation, STATs become phosphorylated by specific receptor kinases, and activated STATs subsequently dimerize and translocate into the nucleus where they regulate gene expression [3]. STAT1 is an important mediator of gamma-interferon (IFNγ), which activates STAT1 by promoting its phosphorylation at
tyrosine 701 residue (Y701) [4]. STAT1 also can be phosphorylated at serine 727 (S727) in response to different stimuli or activators, including ERK, IFNγ, lipopolysaccharide and ultraviolet irradiation [5–7]. STAT1 is frequently down-regulated in various types of human cancer, such as breast cancer, head and neck cancer, multiple myeloma and leukemia [8, 9], and these findings are in line with the postulated role of STAT1 as a tumor suppressor.

Esophageal squamous cell carcinoma (ESCC) is the fourth leading cause of cancer deaths and the fifth most common diagnosed cancer in China [10]. ESCC is particularly prevalent in the Chaoshan area where the age-standardized incidence is approximately 7-fold that of the world population [11]. By studying ESCC cell lines and tumor samples collected from the Chaoshan areas, we previously published that STAT1 is a tumor suppressor of ESCC and this protein is frequently down-regulated in ESCC; importantly, the STAT1\textsuperscript{high} phenotype significantly correlates with a worse clinical outcome [12]. In mouse embryonic fibroblasts, it was found that ERK mediates STAT1 phosphorylation at S727 and increases proteasomal degradation of STAT1 [13]. Nonetheless, the expression of ERK/p-ERK in ESCC and its correlation with STAT1 have not been previously explored. With this background, the main purpose of this study is to find out the correlation of STAT1 and ERK/p-ERK in ESCC.

Here, we identified that ERK is negatively correlated with STAT1. The importance of the ERK/STAT1 axis in ESCC is highlighted by the observation that the ERK\textsuperscript{high}/STAT1\textsuperscript{low} phenotype significantly correlates with a worse clinical outcome in ESCC patients.

RESULTS

ERK mediated STAT1 expression in ESCC cells

In mouse embryonic fibroblasts, it has been described that ERK mediates phosphorylation of STAT1 at the serine 727 residue and increases proteasomal degradation of STAT1 [13]. Thus, we asked if the expression and activation of STAT1 in ESCC is also regulated by the ERK signaling pathway. In keeping with this hypothesis, treatment of KYSE510 and KYSE150 with varying concentrations (0–10 μM) of U0126, a MEK/ERK inhibitor, increased the levels of STAT1 and p-STAT1 in a dose-dependent manner (Figure 1A). At the same time, the level of p-ERK decreased while the total ERK protein level was unchanged. Since KYSE150 expresses a relatively low level of p-STAT1 serine 727 at the steady state, we can’t detect it by using western blots which subjected to a longer exposure. As shown in Figure 1B, transfection of the HA-tagged, MEK1 plasmid resulted in further reduction of STAT1 and p-STAT1 in KYSE150 cell line.

ERK/p-ERK expression in ESCC specimens

To identify the expression of ERK and p-ERK in ESCC specimens, we performed immunohistochemistry staining in a cohort of patient samples. As shown in Figure 2, the p-ERK expression was mostly found in cell nuclei and ERK expression was found in both nuclei and cytoplasm. The stain intensity was categorized as high and low by immune score. Of these 131 ESCC tissues, there is no detectable ERK in 10 cases and p-ERK in 8 cases. For p-ERK, 66 (50.4%) tumors were assessed high and 65 (49.6%) were low. For ERK, 91 (69.5%) tumors were high and 40 (30.5%) tumors were low. For STAT1, 64 (48.9%) were assessed high and 67 (51.1%) were low, as detected in the previous experiments [12].

The clinical significance of p-ERK/ERK expression in ESCC

In our previous study, we found that the expression of STAT1 is prognostically significant [12]. As summarized in Table 1, we correlated p-ERK/ERK expression with various clinical and pathologic parameters and found that both p-ERK and ERK significantly correlated with the clinical stage (p = 0.02 and p = 0.03, respectively, Chi square) as well as the histologic grade (p = 0.04 and p = 0.01, respectively, Fisher’s exact test). We further performed multivariate analysis to evaluate a number of relevant prognostic factors of ESCC, as shown in Table 2. Poor cell differentiation and high p-ERK staining were found to be independent risk factors for ESCC patients (relative risk = 1.45 and 2.27, respectively). Patient survival is illustrated in Figure 3A and 3B, and we found that patients with p-ERK\textsuperscript{low} tumors survived significantly longer than those with p-ERK\textsuperscript{high} (39.5 months versus 29.0 months, p = 0.04). Similar results were obtained when ERK was used instead of p-ERK. Then, we analyzed the survival of these 74 patients categorized into 4 groups based on the differential expression of p-ERK/STAT1, and we found that there is a significant difference (Figure 3C). Specifically, patients with tumors that are p-ERK\textsuperscript{low} and STAT1\textsuperscript{high} expression survived significantly longer than the other 3 groups. Furthermore, patients with tumors that were p-ERK\textsuperscript{high}/STAT1\textsuperscript{low} carried the worst prognosis (Figure 3D and 3E). Similar results were obtained when ERK was used instead of p-ERK (Figure 3F).

The up-regulation of p-ERK/ERK and down-regulation of STAT1 are implicated in cancer progression of ESCC

To identify if the up-regulation of p-ERK/ERK and the down-regulation of STAT1 are implicated in ESCC cancer progression, we assessed the expression
of these three markers in 22 cases of benign esophageal epithelial tissues adjacent to ESCC and 12 carcinoma in situ samples using immunohistochemistry. As illustrated in Figure 4, the expression of p-ERK as well as ERK were significantly lower in benign epithelial tissues (IS: 0.49 ± 0.21), as compared to CIS (IS: 5.47 ± 0.32, p < 0.001). The expression of p-ERK in ESCC (n = 131) was also higher than that of CIS tissues, although the difference did not reach statistical significance (p = 0.10). A similar pattern was found with ERK expression, with gradual decrease from ESCC, CIS to benign esophageal tissues (IS: 7.59 ± 0.26 versus 3.83 ± 0.49 versus 0.52 ± 0.16; p < 0.001). Lastly, the expression of STAT1 was significantly higher in benign esophageal tissues (IS: 194.1 ± 11.93) as compared to CIS (IS: 160 ± 15.84) (p = 0.04), whereas the STAT1 expression level in CIS was also higher than that of ESCC (IS: 106 ± 7.78), although this difference did not reach statistical significance (p = 0.10).

STAT1 inversely correlates with ERK/p-ERK in ESCC tumors

Results from our previous studies led us to hypothesize that the expression of ERK/p-ERK may inversely correlate with that of STAT1 in ESCC tumors. As shown in Table 3, STAT1 inversely correlated with p-ERK and ERK (p = 0.015 and p = 0.001, respectively, Fisher’s exact test). Analysis of our data also indicated a significant correlation between ERK expression and p-ERK expression (Spearman coefficient, r = 0.746; p = 0.001).

DISCUSSION

STAT1, the first member discovered in the family of STAT proteins, was identified as the key mediator for type I and type II IFNs. Accumulating evidence suggested that STAT1 is a tumor suppressor in various cancer models [3, 14]. STAT1 was found to be frequently down-regulated in neoplastic cells, as compared to their adjacent benign tissues in breast cancer, colorectal cancer and liver cancer [15]. Our group also has recently published that STAT1 plays a tumor suppressor role in ESCC [12], in which we found that 43 of 57 (75.4%) ESCC samples examined showed a down-regulation of STAT1 as compared to the case-matched, benign epithelia adjacent to the tumors. In the same study, we found that patients with STAT1 low tumors had a significantly worse clinical outcome; gene

Figure 1: ERK mediated STAT1 expression in ESCC. (A) KYSE510 and KYSE150 cell lines were treated with increasing doses of U0126 for 90 min. Western blot analysis of p-STAT1, STAT1, p-ERK and ERK in total cell lysates are shown. (B) KYSE150 cells were transfected with a constitutive-active MEK expression (HA-ca-MEK) plasmid, and endogenous protein levels of p-STAT1 and STAT1 in the lysates were determined by immunoblotting. Similar results were observed in three independent experiments.
transfection of STAT1 into ESCC cells was found to effectively induce apoptosis, highlighting the biological importance of STAT1 in this tumor.

The ERK pathway is an important, highly conserved family of enzymes associated with cell membrane receptors and regulative targets. An activated ERK cascade controls cell proliferation, differentiation, survival, and apoptosis as well as regulating the cell cycle [16–20]. These cascades also regulate cell meiosis, mitosis, and post mitotic processes in differentiated cells by phosphorylating several molecules, including transcription factors, cytoskeleton elements, apoptosis regulators, translation regulators, and a variety of other signaling-related molecules [21].

The function of ERK in cell proliferation and differentiation has been well documented in various papers. An aberrant ERK cascade activation occurs in a high proportion of human cancers, including human renal cell carcinoma and prostate cancer [22–24]. The inappropriate activation of upstream molecules, such as EGFR, Raf, and Ras, constitute major forces controlling the constitutive activation of the ERK pathway in tumor cells [25–30]. Research identifies this pathway as a promising chemotherapy target. Specifically, the inhibition of the ERK pathway represents an efficient way of blocking proliferation, metastasis, and angiogenesis in cancer cells [31]. Since ERK fulfills an essential role in responding to hepatocyte growth factor (HGF) [32], the obstruction of this pathway downregulates the hypoxia-inducible factor 1a (HIF-1a) [33, 34], a master regulator of angiogenesis, as well as MMP-3/-9/-14 and CD44, important regulators of cell invasion [35].

The expression of ERK in esophageal cancer has been demonstrated in a limited number of papers. In a cohort of patients from the Kazakh population, researchers have found that the expression of ERK is higher in ESCC samples compared to normal tissue, and this up-regulation significantly correlated with lymph nodes metastasis and histologic grade [36]. In this paper, we found high p-ERK expression was a significant risk factor for ESCC patients, however, the total ERK expression did not show significance. The possible reason is that the phosphorylation at both the threonine 202 and tyrosine 204 residues of ERK1 or threonine 185 and tyrosine 187 residues of ERK2 is required for full enzymatic activation of ERK [37]. The activation of ERK plays a more important role in the malignant of ESCC rather than the total expression of ERK.

### Table 1: Correlations between p-ERK and ERK expression and various clinicopathologic parameters in ESCC

| Parameter         | Case NO. | low/high expression |
|-------------------|----------|---------------------|
|                   |          | p-ERK               | ERK                  |
| Age               |          |                     |                     |
| ≤ 57              | 66       | 38/28               | 20/46               |
| > 58              | 65       | 27/38               | 20/45               |
| Gender            |          |                     |                     |
| Male              | 98       | 48/50               | 31/67               |
| Female            | 33       | 17/16               | 9/24                |
| Tumor site        |          |                     |                     |
| Upper             | 13       | 4/9                 | 3/10                |
| Middle            | 104      | 54/50               | 33/71               |
| Lower             | 14       | 7/7                 | 4/10                |
| Differentiation   |          |                     |                     |
| Poor              | 12       | 4/8 *0.04           | 2/10 *0.012         |
| Intermediate      | 75       | 37/38               | 20/55               |
| Well              | 44       | 30/14               | 18/16               |
| Tumor size        |          |                     |                     |
| > 5 cm            | 82       | 40/42               | 25/57               |
| < 5 cm            | 49       | 25/24               | 15/34               |
| Depth of invasion |          |                     |                     |
| T1–T2             | 103      | 55/48               | 28/75               |
| T3–T4             | 28       | 10/18               | 12/16               |
| Lymph metastasis  |          |                     |                     |
| Yes               | 68       | 31/37               | 18/50               |
| No                | 63       | 34/29               | 22/41               |
| Clinical Stage    |          |                     |                     |
| 1                 | 6        | 4/2 *0.02           | 5/1 *0.031          |
| 2                 | 55       | 35/20               | 17/38               |
| 3                 | 64       | 25/39               | 17/47               |
| 4                 | 6        | 1/5                 | 1/5                 |

*p < 0.05.
Based on previous study with MEF cell lines in which ERK was found to promote STAT1 proteasome degradation in mouse embryonic fibroblasts [13], we tested if ERK expression is negatively correlated with STAT1 expression in ESCC. Our data supports this concept. To our knowledge, this current study represents the first example in which ERK is shown to be negatively correlated with STAT1, a tumor suppressor, in human cancers. While the involvement of ERK mediated the expression and activation of STAT1 has not been previously reported in human cancer models. Based on the results of our study, one may hypothesize that the expression and activation of STAT1 may be closely linked to the expression and activation status of ERK. If this turns out to be the case, one may hypothesize that we can downregulate the ERK activation in order to activate STAT1, a apoptosis promoter, to kill the tumor cells.

In conclusion, we have demonstrated that ERK activation in ESCC is negatively correlated with STAT1 expression. In conjunction with our previous publication on the involvement of ERK mediated the expression and activation of STAT1 has not been previously reported in human cancer models. Based on the results of our study, one may hypothesize that the expression and activation of STAT1 may be closely linked to the expression and activation status of ERK. If this turns out to be the case, one may hypothesize that we can downregulate the ERK activation in order to activate STAT1, a apoptosis promoter, to kill the tumor cells.

Figure 2: p-ERK, ERK and STAT1 expression in normal epithelial, carcinoma in situ (CIS) and ESCC patient samples. The esophageal normal epithelial, CIS and carcinoma tissues were stain by Hematoxylin and eosin (H&E). By immunohistochemistry applied to formalin-fixed paraffin-embedded tissues, variable levels of p-ERK, ERK and STAT1 were detected in normal esophageal, CIS and carcinoma examined. (IHC stain, scale bar, 50 μM).
that STAT1 is a tumor suppressor in ESCC, results from this study strongly supports the concept that ERK suppresses the expression of STAT1 in ESCC. This concept is supported by our clinical observation that the expression of ERK significantly correlates with a worse clinical outcome.

MATERIALS AND METHODS

Patient samples

We randomly collected 131 consecutive ESCC tumors at the Shantou Tumor Hospital between 2005 and 2012. All patients underwent potentially curative surgery without preoperative chemotherapy or radiotherapy. In this cohort, 98 were men and 33 were women; the range of age was 36–78 years, with a median of 57 years. Follow-up data was available for 74 patients; most (58, 78.4%) died during the follow-up period (median survival, 31.4 months).

Of the 131 ESCC tumors, 22 case-matched normal esophageal tissues adjacent to the tumors were included in the study. Written informed consents were obtained from patients, and the study was reviewed and approved by the institutional ethics committee.

Immunohistochemistry (IHC)

IHC staining was performed using the Envision Labeled Peroxidase System (Dako, Carpentaria, CA). Consecutive 4 μm thick slices from each sample were deparaffinized in dimethyl benzene, rehydrated through a graded ethanol series and incubated with fresh 3% H₂O₂ for 10 minutes to quench endogenous peroxidase activity. After a rinse in phosphate-buffered saline (PBS), antigen retrieval involved microwave heating. Following incubation with 10 mmol/L citrate buffer (pH 6.0) for 20 minutes, primary antibodies for STAT1 (Cell Signaling, 1:75), phospho-p44/42 MARP (ERK1/2,D13.14.4E) (Cell Signaling, 1:200) and p44/42 MARP (ERK1/2, 137F5) (Cell Signaling, 1:500) were incubated at 4°C overnight. After washing, corresponding secondary antibody (DAKO, Carpentaria, CA) was added for incubation at 37°C for 30 minutes before reaction with diaminobenzidine and counterstaining with haematoxylin.

Two pathologists who were blinded to the clinical outcome examined IHC staining and consensus between the two pathologists in discrepant cases was reached by performing a review under a double-headed microscope. For the evaluation of STAT1 immunostaining, both the intensity and percentage of immunostained cells were described previously [12]. Scoring for the p-ERK and ERK immunostaining was performed as follows: for the proportion of positivity, each case was categorized as: 0 (< 5% positive cells), 1+ (6–25% positive cells), 2+ (26–50% positive cells), 3+ (51–75% positive cells) or 4+ (> 75% positive cells). Each case was categorized as 0 to 3+ based on the average staining intensity. The final scores were based on the multiplication of the proportion score and intensity score, which ranged from 0 to 12. Tumors were considered ERK low or p-ERK low when they were assigned a score of < 6, whereas tumors were considered ERK high or p-ERK high if they had a final score of ≥ 6.

Cell lines

Three human ESCC cell lines, KYSE510 and KYSE150, were used in this study. They were maintained in RPMI 1640 supplemented with 10% fetal bovine serum.
and 1 × antibiotic mixture (Invitrogen, Carlsbad, CA, USA). All cells were cultured at 37°C in a humidified incubator containing 5% CO2.

**Plasmid and drug**

The pBABE-MEK-1 (HA-MEK1) vector was purchased from the Addgene. Mitogen-activated protein kinase kinase (MEK1) inhibitor U0126 was purchased from Cell Signaling (Danvers, MA, USA).

**Westernblot and antibodies**

The preparation of cell lysates for Western blots was done as follows: cells were washed twice with cold phosphate-buffered saline (PBS, pH = 7.0), and scraped in RIPA lysis buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 50 mM Tris pH 8.0) supplemented with 40.0 μg/mL leupeptin, 1 μM peptatin, 0.1 mM phenylmethylsulfonyl-fluoride and sodium orthovanadate. Cell lysates were incubated on ice.

**Figure 3: Kaplan-Meier curves of esophageal cancer patients in different p-ERK, ERK and STAT1 sub-groups.** (A) By Kaplan-Meier analysis, the significant correlation between overall survival and the expression level of p-ERK was found, when the two groups were defined as p-ERK high and p-ERK low. Similar result was obtained in ERK high/low expression patient groups (B). The cohort patients were divided into four sub groups by the STAT1 and p-ERK/ERK expression level, we found that patients with p-ERK high/STAT1 high survived significantly longer than other subgroups (C) and those with p-ERK low/STAT1 low survived significantly shorter than others (D). By Kaplan-Meier analysis, significant correlation between overall survivals was found when the cohort patients were divided into four sub groups by the STAT1 and p-ERK/ERK expression level (E, F).
for 30 minutes and centrifuged for 15 minutes at 15000 g at 4°C. Proteins in the supernatant were then extracted and quantified using the bicinchoninic acid protein assay (Pierce, Rockford, IL). Subsequently, cell lysates were then loaded with 4x loading dye (Tris-HCl pH 7.4, 1% SDS, glycerol, dithiothreitol, and bromophenol blue), electrophoresed on 8% or 10% SDS-polyacrylamide gels, and transferred onto nitrocellulose membranes (Bio-Rad, Richmond, CA, USA). After the membranes were blocked with 5% milk in Tris buffered saline (TBS) with

| STAT1 expression level | p-ERK expression level | High | Low | Total |
|------------------------|------------------------|------|-----|-------|
| High                   | 25                     | 39   | 64  |
| Low                    | 41                     | 26   | 67  |
| Total                  | 66                     | 65   | 131 |

*P < 0.05.

| STAT1 expression level | ERK expression level | High | Low | Total |
|------------------------|---------------------|------|-----|-------|
| High                   | 34                  | 30   | 64  |
| Low                    | 57                  | 10   | 67  |
| Total                  | 91                  | 40   | 131 |

*P = 0.001*.

**Figure 4:** The IHC score of p-ERK (A), ERK (B) and STAT1 (C) in normal tissues, CIS and ESCC are shown. (*p < 0.05, **p < 0.01, ***p < 0.001.)
Tween, they were incubated with primary antibodies. After washings with TBS supplemented with 0.05% Tween-20 for 30 minutes between steps, secondary antibody conjugated with the horseradish peroxidase (Jackson Immunoresearch Laboratories, West Grove, PA, USA) was added to the membrane. The following antibodies were employed: anti-STAT1 (1:1000) and anti-p-STAT1(Tyr-701) (1:1000) and anti-p-STAT1(Ser-701) were purchased from Cell Signaling (Danvers, MA, USA). anti-β-actin (1:1000), anti-phospho-ERK (or p-ERK) (1:1000), anti-ERK (1:1000) and anti-HA, were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Densitometric analysis was performed using the ImageJ analysis system (Bethesda, WA, USA); the values for the STAT1 bands were normalized to those of the β-actin bands.

**Statistical analysis**

Statistical analysis was performed with the SPSS15.0 software. The correlation between ERK/p-ERK and other clinical parameters was evaluated using Chi-square or Student’s t-test. A value of \( p < 0.05 \) was considered as statistically significant.

**CONFLICTS OF INTEREST**

None.

**REFERENCES**

1. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007; 1773:1263–84.

2. Kohno M, Pouysségur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med. 2006; 38:200–11.

3. Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell signaling. 2007; 19:454–65.

4. Ramana CV, Chatterjee-Kishore M, Nguyen H, Stark GR. Complex roles of Stat1 in regulating gene expression. Oncogene. 2008; 19:2619–27.

5. Kovarik P, Mangold M, Ramsauer K, Heidari H, Steinborn R, Zotter A, Levy DE, Müller M, Decker T. Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727phosphorylation, differentially affecting specific target gene expression. EMBO J. 2001; 20:91–100.

6. Ruuska M, Sahilberg AS, Colbert RA, Granfors K, Penttinens MA. Enhanced phosphorylation of STAT1 is dependent on double-stranded RNA-dependent protein kinase signalingin HLA-B27-expressing U937 monocytic cells. Arthritis Rheum. 2012; 64:772–7.

7. Zhang Y, Cho YY, Petersen BL, Zhu F, Dong Z. Evidence of STAT1 phosphorylation modulated by MAPKs, MEK1 and MSK1. Carcinogenesis. 2004; 25:1165–75.

8. Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, Welch MJ, Cardiff RD, Schreiber RD. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res. 2012; 14:16.

9. Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic Lymphocytes. Cancer Immunol Immunother. 2011; 60: 525–35.

10. Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X, He J. Esophageal cancer incidence and mortality in China, 2009. J Thorac Dis. 2013; 5:19–26.

11. Su M, Li XY, Tian DP, Wu MY, Wu XY, Lu SM, Huang HH, Li DR, Zheng ZC, Xu XH. Clinicopathologic analysis of esophageal and cardiac cancers and survey of molecule reexpression on tissue arrays in Chaoshan littoral of China. World J Gastroenterol. 2004; 10:2163–7.

12. Zhang Y, Molavi O, Su M, Lai R. The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma. BMC Cancer. 2014; 14:791.

13. Soond SM, Townsend PA, Barry SP, Knight RA, Latchman DS, Stephanou A.ERK and the F-box protein beta TRCP target STAT1 for degradation. J Biol Chem. 2008; 283:16077–83.

14. Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M, Durrant LG. Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut. 2010; 59:926–33.

15. Huang S, Bucana CD, Van Arsdall M, Fidler JJ. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene. 2002; 21:2504–12.

16. Cobb MH. MAP kinase pathways. Prog Biophys Mol Biol. 1999; 71:479–500.

17. Mazzucchelli C, Vantaggiato C, Ciamei A, Fasano S, Pakhotin P, Krezel W, Welzl H, Wolfer DP, Pagés G, Valverde O, Marowsky A, Porrazzo A, Orban PC, et al. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron. 2002; 34:117.

18. Yao Y, Li W, Wu J, Germann UA, Su MS, Kuida K, Boucher DM. ERK 2 is necessary for mesoderm differentiation. Proc Natl Acad Sci USA. 2003; 100:12759–64.

19. Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, Brambilla R. ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol. 2006; 5:14.

20. Lefloch R, Pouysségur J, Lenormand P. Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol. 2008; 28:511–27.
21. Hoshino R, Chatani Y, Yamori T, Tsuuro T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41/-43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999; 18:813–22.

22. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 1999; 59:279–84.

23. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawauchi M, Kohno M, Yoshida O. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995; 55:4182–7.

24. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002; 7:31–9.

25. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, ujii Y, et al. EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy. Science. 2004; 304:1497–500.

26. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther. 2002; 1:599–606.

27. Downward J. Targeting RAS signaling pathways in cancer therapy. Nature Rev Cancer. 2003; 3:11–12.

28. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949–54.

29. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116:855–67.

30. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med. 2006; 38:200–11.

31. Tanimura S, Chatani Y, Hoshino R, Sato M, Watanabe S, Kataoka T, Nakamura T, Kohno M. Activation of the 41/43 kDa mitogenactivated protein kinase signaling pathway is required for hepatocyte growth factor induced cell scattering. Oncogene. 1998; 17:57–65.

32. Semenza GL. Targeting HIF-1a for cancer therapy. Nature Rev Cancer. 2003; 3:721–32.

33. Richard DE, Berra E, Gotoh E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1a (HIF-1a) and enhance the transcriptional activity of HIF-1. J Biol Chem. 1999; 274: 2631–7.

34. Brahimi-Horn C, Mazure N, Pouyssegur J. Signalling via the hypoxia-inducible factor 1 a requires multiple posttranslational modifications. Cell Signal. 2005; 17:1–9.

35. Tanimura S, Asato K, Fujishiro S, Kohno M. Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem Biophys Res Commun. 2003; 304: 801–6.

36. Cui X, Li S, Li T, Pang X, Zhang S, Jin J, Hu J, Liu C, Yang L, Peng H, Jiang J, Liang W, Suo J, et al. Significance of elevated ERK expression and its positive correlation with EGFR in Kazakh patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7:2382–91.

37. Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ, Sturgill TW. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAPkinase). EMBO J. 1991;10:885–92.